Pharma Intelligence is part of the Informa Intelligence Division of Informa PLC
This is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.
11 Total results for product and free and sample content found
By Jessica Merrill 14 Nov 2022
The pandemic phase will last through late 2021/early 2022, becoming a more seasonal opportunity for several years after, Pfizer management predicted during the company's second quarter call.
27 Nov 2020
Topic Clinical Trials Drug Pricing Sales Earnings Cell & Gene Therapy
By Tom Gallen 17 Nov 2020
Sanofi's recently-appointed Consumer Healthcare head Julie Van Ongevalle says she has identified "untapped potential" for the business to utilize "cutting edge digital platforms." Van Ongevalle revealed her early plans for Sanofi as it reported a drop in Q3 sales.
Topic Sales Earnings Digital Health
By Ian Haydock 17 Nov 2020
Join us for a quick audio roundup of major developments in the international biopharma industry over the past week, as covered by Scrip's global team.
Topic Sales Earnings
By Mandy Jackson 17 Nov 2020
Merck’s third quarter beat analyst consensus and the company raised its guidance. The COVID-19-battered vaccines business began to improve but Gardasil’s recovery was slower than expected.
By Jessica Merrill 17 Nov 2020
Highly anticipated data from Pfizer's Phase III COVID-19 vaccine trial does not appear on track to be made publicly available in October as previously expected.
By Andy Smith 28 Oct 2020
Early in 2020, company guidance was that pandemic-related effects would have dissipated in the third quarter. Issues specific to J&J and Roche leave this broad conclusion still up in the air
Topic Sales Earnings Coronavirus
By Joseph Haas 01 May 2020
With efficacy data in hand, Gilead wants to balance economic sustainability with broad availability of remdesivir for COVID-19 patients. The firm did not alter guidance on Q1 earnings call.
By Kevin Grogan 30 Apr 2020
Bayer has beaten analyst forecasts for the first quarter but says the uncertainties brought about by the coronavirus pandemic prevent it from issuing financial guidance for the full year.
Topic Coronavirus Sales Earnings
No Records Found
Getting a demo tailored to your needs is the best way to see how our solutions will help you gain an advantage.
Request live demo now:
Our team is ready to hear from you for a particular request or area of interest. Please do not hesitate to reach out and discuss.
Contact us for product technical and account support.
Have an immediate and specific information need?
Browse and buy from 1000s of analysis and research reports now: